Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2998422 | 0.83 | NLRP3 (0.46) | NLRP3SMN1; SMN2CYP3A4ALDH1A1MAPT | |
| Racemethionine SCHEMBL4374692 | 0.83 | NLRP3 (0.36) | NLRP3NR4A1EGFR | |
| SCHEMBL13038941 | 0.78 | NLRP3 (0.42) | NLRP3ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL3000425 | 0.77 | NLRP3 (0.43) | NLRP3ALDH1A1LMNANPC1MAPT | |
| SCHEMBL9181008 | 0.77 | ALDH1A1 (0.47) | NLRP3SMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL21439368 | 0.74 | NLRP3 (0.44) | NLRP3NR4A1EGFRSMN1; SMN2TDP1 | |
| SCHEMBL11965264 | 0.72 | EGFR (0.58) | NLRP3NR4A1EGFRCA12CA1 | |
| SCHEMBL6988206 | 0.71 | NLRP3 (0.45) | NLRP3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL136459 | 0.70 | EGFR (0.56) | NLRP3NR4A1EGFRCA12CA1 | |
| SCHEMBL27797500 | 0.69 | EGFR (0.74) | NR4A1EGFRCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825124-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-11-02 | — | — | US | disclosed |
| US-7786123-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-08-31 | — | — | US | disclosed |
| US-20090318463-A1 | Indolylmaleimide Derivatives | ALBERT RAINER | 2009-12-24 | — | — | US | disclosed |
| EP-1337527-B1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-20070184061-A1 | Indolylmaleimide derivatives | ALBERT RAINER | 2007-08-09 | — | — | US | disclosed |
| US-20070155817-A1 | Indolylmaleimide derivatives | ALBERT RAINER | 2007-07-05 | — | — | US | disclosed |
| US-7220774-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2007-05-22 | — | — | US | disclosed |
| US-20040053949-A1 | Indolylmaleimide derivatives | ALBERT RAINER (CH) | 2004-03-18 | — | — | US | disclosed |
| US-6645970-B2 | Preventing T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer | NOVARTIS AG (CH) | 2003-11-11 | — | — | US | disclosed |
| US-20030069424-A1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318463-A1 | Indolylmaleimide Derivatives | NFATC1, INMT, IDO1 | NLRP3 592/4885NR4A1 2033/4885EGFR 3954/4885 |
| US-20030069424-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | NLRP3 592/4885NR4A1 2033/4885EGFR 3954/4885 |
| US-20040053949-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | NLRP3 592/4885NR4A1 2033/4885EGFR 3954/4885 |
| US-20070155817-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | NLRP3 592/4885NR4A1 2033/4885EGFR 3954/4885 |
| US-20070184061-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | NLRP3 592/4885NR4A1 2033/4885EGFR 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.